_id
69105587ccc777a4e85d55d9
Ticker
CSBR
Name
Champions Oncology Inc
Exchange
NASDAQ
Address
One University Plaza, Hackensack, NJ, United States, 07601
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.championsoncology.com
Description
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Last Close
6.32
Volume
2133
Current Price
6.72
Change
6.329113924050624
Last Updated
2025-11-29T11:53:55.428Z
Image
data:image/webp;base64,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
Ipo Date
2003-01-10T00:00:00.000Z
Market Cap
90176272
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
5
Target Price
12
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-07-31
Revenue
13995000
Cost Of Revenue
7995000
Gross Profit
-7995000
Operating Expenses
6527000
Operating Income
-527000
Interest Expense
-
Pretax Income
-452000
Net Income
-466000
Eps
-0.03379649029975456
Dividends Per Share
-
Shares Outstanding
13788421
Income Tax Expense
14000
EBITDA
-527000
Operating Margin
-3.7656305823508394
Total Other Income Expense Net
75000
Cash
10325000
Short Term Investments
-
Receivables
9474000
Inventories
-
Total Current Assets
21014000
Property Plant Equipment
9001000
Total Assets
30546000
Payables
4845000
Short Term Debt
1506000
Long Term Debt
-
Total Liabilities
27008000
Equity
3508000
Depreciation
358000
Change In Working Capital
199000
Cash From Operations
600000
Capital Expenditures
46000
Cash From Investing
-46000
Cash From Financing
-14000
Net Change In Cash
540000
PE
31.1429
PB
26.41338143671608
ROE
-13.283922462941847
ROA
-1.5255679958095985
FCF
554000
Fcf Percent
0.039585566273669166
Piotroski FScore
2
Health Score
12
Deep Value Investing Score
4.5
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
3.5
Growth Investing Score
3.5
Momentum Investing Score
3.5
Net Net Investing Score
3.5
Quality Investing Score
3
Value Investing Score
2.5
Quarters > 0 > quarter
2025-07-31
Quarters > 0 > income Statement > revenue
13995000
Quarters > 0 > income Statement > cost Of Revenue
7995000
Quarters > 0 > income Statement > gross Profit
-7995000
Quarters > 0 > income Statement > operating Expenses
6527000
Quarters > 0 > income Statement > operating Income
-527000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-452000
Quarters > 0 > income Statement > net Income
-466000
Quarters > 0 > income Statement > eps
-0.03379649029975456
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
13788414
Quarters > 0 > income Statement > income Tax Expense
14000
Quarters > 0 > income Statement > EBITDA
-527000
Quarters > 0 > income Statement > operating Margin
-3.7656305823508394
Quarters > 0 > income Statement > total Other Income Expense Net
75000
Quarters > 0 > balance Sheet > cash
10325000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
9474000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
21014000
Quarters > 0 > balance Sheet > property Plant Equipment
9001000
Quarters > 0 > balance Sheet > total Assets
30546000
Quarters > 0 > balance Sheet > payables
4845000
Quarters > 0 > balance Sheet > short Term Debt
1506000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
27008000
Quarters > 0 > balance Sheet > equity
3508000
Quarters > 0 > cash Flow > net Income
-466000
Quarters > 0 > cash Flow > depreciation
358000
Quarters > 0 > cash Flow > change In Working Capital
199000
Quarters > 0 > cash Flow > cash From Operations
600000
Quarters > 0 > cash Flow > capital Expenditures
46000
Quarters > 0 > cash Flow > cash From Investing
-46000
Quarters > 0 > cash Flow > cash From Financing
-14000
Quarters > 0 > cash Flow > net Change In Cash
540000
Quarters > 0 > ratios > PE
-0.03379649029975456
Quarters > 0 > ratios > PB
26.41338143671608
Quarters > 0 > ratios > ROE
-13.283922462941847
Quarters > 0 > ratios > ROA
-1.5255679958095985
Quarters > 0 > ratios > FCF
554000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.039585566273669166
Quarters > 0 > health Score
12
Quarters > 1 > quarter
2025-04-30
Quarters > 1 > income Statement > revenue
12355000
Quarters > 1 > income Statement > cost Of Revenue
7271000
Quarters > 1 > income Statement > gross Profit
5084000
Quarters > 1 > income Statement > operating Expenses
7091000
Quarters > 1 > income Statement > operating Income
-2006000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-1964000
Quarters > 1 > income Statement > net Income
-1834000
Quarters > 1 > income Statement > eps
-0.1333471479233581
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
13753575
Quarters > 1 > income Statement > income Tax Expense
-129000
Quarters > 1 > income Statement > EBITDA
-1320000
Quarters > 1 > income Statement > operating Margin
-16.2363415621206
Quarters > 1 > income Statement > total Other Income Expense Net
43000
Quarters > 1 > balance Sheet > cash
9785000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
11234000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
22369000
Quarters > 1 > balance Sheet > property Plant Equipment
9455000
Quarters > 1 > balance Sheet > total Assets
32344000
Quarters > 1 > balance Sheet > payables
4248000
Quarters > 1 > balance Sheet > short Term Debt
1471000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
28572000
Quarters > 1 > balance Sheet > equity
3772000
Quarters > 1 > cash Flow > net Income
-1835000
Quarters > 1 > cash Flow > depreciation
394000
Quarters > 1 > cash Flow > change In Working Capital
7727000
Quarters > 1 > cash Flow > cash From Operations
6868000
Quarters > 1 > cash Flow > capital Expenditures
253000
Quarters > 1 > cash Flow > cash From Investing
-253000
Quarters > 1 > cash Flow > cash From Financing
-32000
Quarters > 1 > cash Flow > net Change In Cash
6583000
Quarters > 1 > ratios > PE
-0.1333471479233581
Quarters > 1 > ratios > PB
24.502657476139976
Quarters > 1 > ratios > ROE
-48.621420996818664
Quarters > 1 > ratios > ROA
-5.670294335889191
Quarters > 1 > ratios > FCF
6615000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.5354107648725213
Quarters > 1 > health Score
28
Quarters > 2 > quarter
2025-01-31
Quarters > 2 > income Statement > revenue
17039000
Quarters > 2 > income Statement > cost Of Revenue
6617000
Quarters > 2 > income Statement > gross Profit
10422000
Quarters > 2 > income Statement > operating Expenses
5923000
Quarters > 2 > income Statement > operating Income
4499000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
4518000
Quarters > 2 > income Statement > net Income
4495000
Quarters > 2 > income Statement > eps
0.3129154221984359
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
14364904
Quarters > 2 > income Statement > income Tax Expense
23000
Quarters > 2 > income Statement > EBITDA
4916000
Quarters > 2 > income Statement > operating Margin
26.404131697869595
Quarters > 2 > income Statement > total Other Income Expense Net
19000
Quarters > 2 > balance Sheet > cash
3202000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
15782000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
19697000
Quarters > 2 > balance Sheet > property Plant Equipment
10410000
Quarters > 2 > balance Sheet > total Assets
30627000
Quarters > 2 > balance Sheet > payables
5093000
Quarters > 2 > balance Sheet > short Term Debt
1434000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
25158000
Quarters > 2 > balance Sheet > equity
5469000
Quarters > 2 > cash Flow > net Income
4495000
Quarters > 2 > cash Flow > depreciation
398000
Quarters > 2 > cash Flow > change In Working Capital
-4917000
Quarters > 2 > cash Flow > cash From Operations
490000
Quarters > 2 > cash Flow > capital Expenditures
42000
Quarters > 2 > cash Flow > cash From Investing
-42000
Quarters > 2 > cash Flow > cash From Financing
0
Quarters > 2 > cash Flow > net Change In Cash
448000
Quarters > 2 > ratios > PE
0.3129154221984359
Quarters > 2 > ratios > PB
17.650787142073504
Quarters > 2 > ratios > ROE
82.19052843298591
Quarters > 2 > ratios > ROA
14.676592549058022
Quarters > 2 > ratios > FCF
448000
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
0.026292622806502727
Quarters > 2 > health Score
50
Quarters > 3 > quarter
2024-10-31
Quarters > 3 > income Statement > revenue
13489000
Quarters > 3 > income Statement > cost Of Revenue
7072000
Quarters > 3 > income Statement > gross Profit
6417000
Quarters > 3 > income Statement > operating Expenses
5329000
Quarters > 3 > income Statement > operating Income
732000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
739000
Quarters > 3 > income Statement > net Income
728000
Quarters > 3 > income Statement > eps
0.051937107872160236
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
14016953
Quarters > 3 > income Statement > income Tax Expense
11000
Quarters > 3 > income Statement > EBITDA
1131000
Quarters > 3 > income Statement > operating Margin
5.426643932092817
Quarters > 3 > income Statement > total Other Income Expense Net
7000
Quarters > 3 > balance Sheet > cash
2754000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
10470000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
14084000
Quarters > 3 > balance Sheet > property Plant Equipment
10636000
Quarters > 3 > balance Sheet > total Assets
25240000
Quarters > 3 > balance Sheet > payables
4854000
Quarters > 3 > balance Sheet > short Term Debt
1401000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
24559000
Quarters > 3 > balance Sheet > equity
681000
Quarters > 3 > cash Flow > net Income
728000
Quarters > 3 > cash Flow > depreciation
399000
Quarters > 3 > cash Flow > change In Working Capital
1927000
Quarters > 3 > cash Flow > cash From Operations
-283000
Quarters > 3 > cash Flow > capital Expenditures
94000
Quarters > 3 > cash Flow > cash From Investing
-94000
Quarters > 3 > cash Flow > cash From Financing
239000
Quarters > 3 > cash Flow > net Change In Cash
-138000
Quarters > 3 > ratios > PE
0.051937107872160236
Quarters > 3 > ratios > PB
138.31706925110132
Quarters > 3 > ratios > ROE
106.90161527165934
Quarters > 3 > ratios > ROA
2.884310618066561
Quarters > 3 > ratios > FCF
-377000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.027948698939876938
Quarters > 3 > health Score
41
Valuation > metrics > PE
31.1429
Valuation > metrics > PB
26.41338143671608
Valuation > final Score
12.628519999999995
Valuation > verdict
402.5% Overvalued
Profitability > metrics > ROE
-13.283922462941847
Profitability > metrics > ROA
-2.2175692395545825
Profitability > metrics > Net Margin
-0.03329760628795998
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
7.698973774230331
Risk > metrics > Interest Coverage
-7.026666666666666
Risk > final Score
-22
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.3087702723980477
Liquidity > metrics > Quick Ratio
3.3087702723980477
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
0
Prev Profitabilities > 1
100
Prev Profitabilities > 2
64
Prev Risks > 0
-6
Prev Risks > 1
46
Prev Risks > 2
13
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:22:09.326Z
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AInvestors in Champions Oncology (NASDAQ:CSBR) from five years ago are still down 41%, even after 11% gain this past week simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-07-31)
Rating:
STRONG BUY
Target Price:
$12
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-07-31)
Health Score
Price to Earnings Ratio (P/E)
-
Medium
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 44.54% of the total shares of Champions Oncology Inc
1.
Battery Management Corp(17.5631%)
since
2025/06/30
2.
NEA Management Company, LLC(12.4287%)
since
2025/06/30
3.
Tocqueville Asset Management L.P.(2.9001%)
since
2025/06/30
4.
Vanguard Group Inc(2.3718%)
since
2025/06/30
5.
Vanguard Total Stock Mkt Idx Inv(1.6731%)
since
2025/07/31
6.
Renaissance Technologies Corp(1.1027%)
since
2025/03/31
7.
BlackRock Inc(0.8403%)
since
2025/03/31
8.
Morgan Stanley - Brokerage Accounts(0.6413%)
since
2025/03/31
9.
Geode Capital Management, LLC(0.5449%)
since
2025/03/31
10.
Millennium Management LLC(0.4831%)
since
2025/03/31
11.
Vanguard Institutional Extnd Mkt Idx Tr(0.4571%)
since
2025/07/31
12.
Northern Trust Corp(0.3914%)
since
2025/03/31
13.
Acadian Asset Management LLC(0.2866%)
since
2025/03/31
14.
HighTower Advisors, LLC(0.255%)
since
2025/06/30
15.
Susquehanna International Group, LLP(0.2461%)
since
2025/06/30
16.
Fidelity Extended Market Index(0.2334%)
since
2025/07/31
17.
Bank of New York Mellon Corp(0.194%)
since
2025/03/31
18.
State Street Corp(0.19%)
since
2025/03/31
19.
Bank of America Corp(0.1833%)
since
2025/03/31
20.
Hillsdale Investment Management Inc.(0.182%)
since
2025/06/30
21.
Jane Street Group LLC(0.167%)
since
2025/03/31
22.
Dimensional Fund Advisors, Inc.(0.1625%)
since
2025/06/30
23.
iShares Micro-Cap ETF(0.1473%)
since
2025/08/29
24.
O'Shaughnessy Asset Management LLC(0.1346%)
since
2025/06/30
25.
Fidelity Total Market Index(0.0886%)
since
2025/07/31
26.
Fidelity Nasdaq Composite Index(0.0795%)
since
2025/07/31
27.
Extended Equity Market Fund K(0.0786%)
since
2025/06/30
28.
Fidelity Series Total Market Index(0.063%)
since
2025/07/31
29.
Spartan Extended Market Index Pool F(0.0502%)
since
2025/07/31
30.
Schwab Total Stock Market Index(0.0497%)
since
2025/07/31
31.
Northern Trust Extended Eq Market Idx(0.0486%)
since
2025/06/30
32.
NT Ext Equity Mkt Idx Fd - L(0.0486%)
since
2025/06/30
33.
Vanguard Instl Ttl Stk Mkt Idx InstlPls(0.0473%)
since
2025/07/31
34.
NT Ext Equity Mkt Idx Fd - NL(0.0428%)
since
2025/06/30
35.
Northern Small Cap Core I(0.0378%)
since
2025/06/30
36.
NT Ext Equity Mkt Idx Fd - DC - NL - T2(0.0333%)
since
2025/06/30
37.
Spartan Total Market Index Pool G(0.0302%)
since
2025/07/31
38.
State St US Extended Mkt Indx NL Cl C(0.0203%)
since
2025/07/31
39.
NT Quality SCC US Fund - L(0.019%)
since
2025/06/30
40.
NT Quality Small Cap Core(0.019%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-07-31)
(Last Updated 2025-07-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-07-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-07-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.